Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
Available: 10/17/18, Expires: 10/16/22

Our lab translates advances in cancer biology into effective targeted therapies for adult and pediatric sarcomas. Current priorities include: 1) rational combination therapies; 2) new strategies for targeting oncogenic tyrosine kinases and the dysregulated cell cycle; 3) maximizing therapeutic response by targeting mechanisms of genetic/biologic progression in sarcomas. The student can participate in designing clinical trials of drugs validated in the laboratory studies. We lead several international research consortia in these fields, leading to rich collaborations and interactions.

Characterizing Dystrophin as a Prognostic Biomarker in Surgically-resected GIST
Summer, 04/01/13 - 08/19/13

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA127003 (BASS, ADAM JOEL) Apr 1, 2007 - May 31, 2024
    NIH/NCI
    SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER
    Role: Co-Principal Investigator
  2. R01CA072791 (FLETCHER, JONATHAN A) Sep 19, 1997 - Aug 31, 2000
    NIH/NCI
    TRANSLOCATION OF 8-13 IN STEM-CELL LEUKEMIA/LYMPHOMA
    Role: Principal Investigator
  3. P01CA068484 (SALLAN, STEPHEN E) Aug 1, 1997 - Jul 31, 2000
    NIH/NCI
    Therapeutic Index of Acute Lymphoblastic Leukemia
    Role: Co-Principal Investigator
  4. R01CA068376 (FLETCHER, JONATHAN A) Apr 5, 1996 - Mar 31, 1999
    NIH/NCI
    TUMOR SUPPRESSOR LOCI IN MESOTHELIOMA
    Role: Principal Investigator
  5. P20NS031110 (BLACK, PETER M) Sep 30, 1992 - Sep 29, 1995
    NIH/NINDS
    CHARACTERIZING AND INHIBITING ASTROCYTOMA GROWTH
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Atiq MA, Davis JL, Hornick JL, Dickson BC, Fletcher CDM, Fletcher JA, Folpe AL, Mariño-Enríquez A. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Mod Pathol. 2020 Jul 15. PMID: 32669612.
    Citations:    
  2. García-Valverde A, Rosell J, Serna G, Valverde C, Carles J, Nuciforo P, Fletcher JA, Arribas J, Politz O, Serrano C. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Mol Cancer Ther. 2020 06; 19(6):1289-1297. PMID: 32371592.
    Citations:    
  3. Serrano C, Vivancos A, López-Pousa A, Matito J, Mancuso FM, Valverde C, Quiroga S, Landolfi S, Castro S, Dopazo C, Sebio A, Virgili AC, Menso MM, Martín-Broto J, Sansó M, García-Valverde A, Rosell J, Fletcher JA, George S, Carles J, Arribas J. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. BMC Cancer. 2020 Feb 05; 20(1):99. PMID: 32024476.
    Citations:    
  4. Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer. 2020 Feb; 122(3):372-381. PMID: 31776458.
    Citations:    
  5. Serrano C, Fletcher JA. Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget. 2019 Oct 29; 10(59):6286-6287. PMID: 31695836.
    Citations:    
  6. Pang Y, Xie F, Cao H, Wang C, Zhu M, Liu X, Lu X, Huang T, Shen Y, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher JA, Wang Y. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2019 11 05; 116(45):22746-22753. PMID: 31636198.
    Citations: